Today: September 27, 2016, 5:36 pm
  
Finance

EVP-6124 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 - new market research report published

companiesandmarkets.com
companiesandmarkets.com
EVP-6124 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 - a new market research report on companiesandmarkets.com

 

PR-Inside.com: 2014-04-28 15:51:01
EVP-6124 (Alzheimer´s Disease) - Forecast and Market Analysis to 2022 - We have released our new PharmaPoint Drug Evaluation report, "EVP-6124 (Alzheimer´s Disease) - Forecast and Market Analysis to 2022". There are no long-term effective therapies for Alzheimer´s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.

Scope

- Overview of AD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on EVP-6124 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for EVP-6124 for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for AD
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of EVP-6124 performance
- Obtain sales forecast for EVP-6124 from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Press Information


Published by
Mike King
London: +44 (0) 203 086 8600
e-mail
www.companiesandmarkets.com



# 455 Words
Related Articles
 
More From Finance
P2P lending platform Monexo partners with IDBI-Trusteeship [..]
For Immediate Release: 2nd September 2016 MUKESH BUBNA, CEO Monexo Fintech Pvt Limited www.monexo.co/in mukesh.bubna@monexo.co P2P [..]
Day Trade to Win New September Class [..]
Sold Out? New Class Added – On September 6, 2016, DayTradeToWin.com is launching a brand new eight-week trading boot camp [..]
FTM (Forget The Market) Reopens 3 Shares [..]
Port Vila, Vanuatu, 28th July 2016 - Investment firm FTM today announced the reopening of three separate share options, projected [..]
Ex-Citibanker Launching Online P2P marketplace in India [..]
A study conducted by World Bank shows that MSMEs in India face an estimated credit gap of INR 20.9 trillion [..]
New Frontier Portfolios Top Morningstar Rankings
New Frontier’s global strategic portfolios topped the Global Balanced Strategic/All-Inclusive category of the latest Morningstar ETF [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.